Recombinant human platelet‐derived growth factor improves root coverage of a collagen matrix for multiple adjacent gingival recessions: A triple‐blinded, randomized, placebo‐controlled trial

• Published in: Journal of clinical periodontology Vol. 49; no. 11; pp. 1169 - 1184
• Main Authors: Tavelli, Lorenzo, Barootchi, Shayan, Rodriguez, Maria Vera, Mancini, Leonardo, Majzoub, Jad, Travan, Suncica, Sugai, Jim, Chan, Hsun‐Liang, Kripfgans, Oliver, Wang, Hom‐Lay, Giannobile, William V.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-11-2022
• Subjects: Collagen; Collagen - therapeutic use; collagen matrix; Connective Tissue; Esthetics, Dental; Gingiva; gingival recession; Gingival Recession - drug therapy; Gingival Recession - surgery; Growth factors; Humans; Original; Patients; Placebos; Platelet-Derived Growth Factor; Platelets; randomized clinical trial; root coverage; Therapy; Treatment Outcome; root coverage; collagen matrix; platelet-derived growth factor; randomized clinical trial; gingival recession
• ISSN: 0303-6979; 1600-051X
• DOI: 10.1111/jcpe.13706

Aim
To evaluate the efficacy of recombinant human platelet‐derived growth factor (rhPDGF)‐BB combined with a cross‐linked collagen matrix (CCM) for the treatment of multiple adjacent gingival recession type 1 defects (MAGRs) in combination with the coronally advanced flap (CAF).
Materials and Methods
Thirty patients were enrolled in this triple‐blind, randomized, placebo‐controlled trial and treated with either CAF + CCM + rhPDGF, or CAF + CCM + saline. The primary outcome was mean root coverage (mRC) at 6 months. Complete root coverage, gain in gingival thickness (GT), keratinized tissue width, volumetric and ultrasonographic changes, and patient‐reported outcome measures were also assessed. Mixed‐modelling regression analyses were used for statistical comparisons.
Results
At 6 months, the mRC of the CCM + rhPDGF and CCM alone groups were 88.25% and 77.72%, respectively (p = .02). A significant gain in GT was consistently observed for both treatment arms, and more so for the patients receiving the matrix containing rhPDGF through time (0.51 vs. 0.80 mm, on average, p = .01). The rhPDGF + CCM treated patients presented greater volume gain, higher soft tissue thickness, and a superior aesthetic score.
Conclusion
rhPDGF enhances the clinical, volumetric, and aesthetic outcomes of MAGRs above the results achieved with CAF + CCM alone (ClinicalTrials.gov NCT04462237).